PMID- 27796020
OWN - NLM
STAT- MEDLINE
DCOM- 20171106
LR  - 20211204
IS  - 1724-5990 (Electronic)
IS  - 0393-5590 (Linking)
VI  - 33
IP  - 5
DP  - 2016 Sep-Oct
TI  - [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin 
      analogues and mTOR inhibitors].
LID - gin/33.5.19 [pii]
AB  - Recent advances in the understanding of the molecular mechanisms underlying 
      autosomal dominant polycystic kidney disease (ADPKD) set the stage for the 
      development of various treatments aimed to arrest or delay disease progression. 
      In particular, clinical trials showed that the use of somatostatin analogues in 
      patients with ADPKD is able to slow down the increase in total kidney volume and 
      the progressive decline in renal function over the long-term. Treatment with 
      these agents is generally well tolerated and it also enables to control cyst 
      growth in the liver in patients with this extra-renal manifestation of the 
      disease. By contrast, mammalian target of rapamycin (mTOR) inhibitors, although 
      promising in different experimental models of kidney and liver disease, in most 
      clinical studies they were not effective in slowing cystic kidney growth and/or 
      improving the progressive renal function decline in patients with ADPKD. Therapy 
      with mTOR inhibitors is also limited by the elevated incidence of adverse events, 
      which frequently requires drug withdrawal or dose reduction, eventually 
      nullifying the potential renoprotective effect.
FAU - Perico, Norberto
AU  - Perico N
FAU - Cortinovis, Monica
AU  - Cortinovis M
FAU - Remuzzi, Giuseppe
AU  - Remuzzi G
LA  - ita
PT  - Journal Article
TT  - Trattamento della malattia policistica autosomica dominanate del rene (ADPKD): 
      analoghi della somatostatina e inibitori mTOR.
PL  - Italy
TA  - G Ital Nefrol
JT  - Giornale italiano di nefrologia : organo ufficiale della Societa italiana di 
      nefrologia
JID - 9426434
RN  - 51110-01-1 (Somatostatin)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Humans
MH  - Polycystic Kidney, Autosomal Dominant/*drug therapy
MH  - Practice Guidelines as Topic
MH  - Somatostatin/*analogs & derivatives
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
EDAT- 2016/11/01 06:00
MHDA- 2017/11/07 06:00
CRDT- 2016/11/01 06:00
PHST- 2016/11/01 06:00 [pubmed]
PHST- 2017/11/07 06:00 [medline]
PHST- 2016/11/01 06:00 [entrez]
AID - gin/00245.19 [pii]
PST - ppublish
SO  - G Ital Nefrol. 2016 Sep-Oct;33(5):gin/33.5.19.